Two FDA guidance documents aim to help pharma companies show the value of their drugs to payers beyond what's included in FDA labeling.
Thanks to legalization, a new breed of startups are changing the nature of cannabis advertising.
The Food and Drug Administration regulates more than a third of the U.S. economy. And its new commissioner, Scott Gottlieb, is trying to shake up how it does so.
FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW
Although if approved, it's not likely to launch in the U.S. for quite some time.
Once Attorney General Jeff Sessions reversed the Cole memo, NORML began applying pressure both locally and nationally for changes in marijuana laws.
As we continue to debate the proper size and role of government in society, cast your eyes on recent polls by Gallup and Pew that found the majority of Americans felt their income tax was fair.
The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.
Alex Azar, previously a senior executive at Eli Lilly, proposed granting Part B the authority to negotiate lower prices.
The FDA's Office of Prescription Drug Promotion issued a warning letter to Amherst Pharmaceuticals and Magna Pharmaceutical.
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
AbbVie to pay $140 million to AndroGel patient; Trump likely to roll back birth-control mandate; patients more likely to respond to expensive drugs
Only three of the seven FDA-approved biosimilars are available for sale; Teva to sell off women's health portfolio; the FDA approves GSK's COPD combo
The OPDP has only issued two letters in 2017, compared to 11 last year.
Johnson & Johnson has breached the U.K.'s drug regulation code in three places in promotions for smoking cessation product Nicorette.
Jury says AbbVie fraudulently misrepresented risks of AndroGel; Celgene settles False Claims Act lawsuit; Amgen reports more Repatha prescribers
Former sales reps for Insys plead guilty to kickback allegations; digital health funding on the rise; PhRMA launches campaign about drug costs
The FDA recently proposed studies designed to determine how disclosures in drug ads affect how viewers frame information.
The drugmaker has been handed a "public reprimand" by the U.K.'s Prescription Medicines Code of Practice Authority after the creative director of an unnamed agency used the company's patient support materials on its website.
The ad-tax deduction is likely once again on the table.
Sandoz counsel argued that Amgen's position "wrongly delays the marketing of every biosimilar."
PhRMA worked with WPP Health & Wellness and Young & Rubicam on creative for the ads.
Lawmaker wants better enforcement of TV ads placed by lawyers; more toddlers are taking antipsychotics; Neurocrine puts off price disclosure of new drug
The committee is seeking information about the companies' sales and marketing strategies.
Veeva is countersuing QuintilesIMS in the wake of allegations that Veeva mishandled its proprietary data.
PhRMA, BIO, and the Medical Information Working Group filed a citizen petition over a final rule they say raises risks for drugmakers.
But it may also increase the reporting burden for drugmakers.
The regulator is providing examples of appropriate off-label communications.
The agency issued 11 enforcement letters last year.
Judge halts Praluent sales; clinical-trial data for Diclegis in question; cancer drugs to make up larger portion of total drug spending